Gene expression markers for colorectal cancer prognosis
View Patent ↗A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject.
1. A method of predicting clinical outcome without treatment with chemotherapy for a human subject diagnosed with colorectal cancer following surgical resection of said cancer, comprising:
determining a normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of a positive clinical outcome without treatment with chemotherapy for said human subject based on said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, wherein said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, is negatively correlated with an increased likelihood of a positive clinical outcome without treatment with chemotherapy.
2. The method of claim 1 , further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, Ki-67, CMYC, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is negatively correlated with an increased likelihood of a positive clinical outcome without treatment with chemotherapy; and
wherein said normalized expression level of each of Ki-67, CMYC, and MYBL2 is positively correlated with an increased likelihood of a positive clinical outcome without treatment with chemotherapy.
3. The method of claim 1 , wherein said normalized expression level of an RNA transcript of EFNB2 is determined using a PCR-based method.
4. The method of claim 1 , wherein said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, is normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.
5. The method of claim 1 , wherein said clinical outcome is expressed in terms of Recurrence-Free Interval (RFI), Overall Survival (OS), Disease-Free Survival (DFS), or Distant Recurrence-Free Interval (DRFI).
6. The method of claim 1 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colorectal cancer.
7. The method of claim 1 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.
8. The method of claim 1 , further comprising the step of creating a report summarizing said prediction.
9. A method of predicting in a human subject diagnosed with Dukes B (stage II) or Dukes C (stage III) colorectal cancer a likelihood of recurrence of colorectal cancer without treatment with chemotherapy following surgical resection of said cancer, comprising:
determining the normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, in a biological sample comprising cancer cells obtained from said human subject, and;
predicting the likelihood of recurrence of colorectal cancer without treatment with chemotherapy for the human subject based on said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, wherein said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, is positively correlated with an increased likelihood of recurrence of colorectal cancer without treatment with chemotherapy.
10. The method of claim 9 , further comprising determining a normalized expression level of an RNA transcript, or an expression product thereof, of one or more of BGN, Ki-67, CMYC, MYBL2, FAP, INHBA, and GADD45B in the biological sample;
wherein said normalized expression level of each of BGN, FAP, INHBA, and GADD45B is positively correlated with an increased likelihood of recurrence of colorectal cancer without treatment with chemotherapy; and
wherein said normalized expression level of each of Ki-67, CMYC, and MYBL2 is negatively correlated with an increased likelihood of recurrence of colorectal cancer without treatment with chemotherapy.
11. The method of claim 9 , wherein said normalized expression level of an RNA transcript of EFNB2 is determined using a PCR-based method.
12. The method of claim 9 , wherein if said likelihood of recurrence of colorectal cancer is increased, said human subject is subjected to further therapy following said surgical resection.
13. The method of claim 9 , wherein said further therapy is chemotherapy and/or radiation therapy.
14. The method of claim 9 , further comprising the step of creating a report summarizing said prediction.
15. The method of claim 9 , wherein said normalized expression level of an RNA transcript of EFNB2, or an expression product thereof, is normalized relative to the expression level of an RNA transcript, or an expression product thereof, of at least one reference gene.
16. The method of claim 9 , wherein said colorectal cancer is Dukes B (stage II) or Dukes C (stage III) colon cancer.